Atrial Fibrillation – Regeneron R9933-CVA-2495
Have Atrial Fibrillation and are at a High Risk of Stroke?
See if an Atrial Fibrillation Study is Right for You.
Profound Research is enrolling a study that is assessing stroke and blood clot prevention with investigational medications in adults with Atrial Fibrillation.
To be eligible to participate, you must:
- Be at least 18 years of age
- Be diagnosed with Atrial Fibrillation or Atrial Flutter
- Be at a moderate to high risk of stroke
- Be unsuitable for oral anticoagulation therapy; this consists of Dabigatran, Apixaban, Rivaroxaban, and Edoxaban
Additional criteria apply.
Qualified participants will receive:
- Study-related care and study medication at no cost
- Financial compensation for time and travel expenses
Number of visits and duration of study:
- You will be in the study for up to 30 months with regular clinic visits as often as every 2 weeks
Please note that this clinical trial will use an investigational drug product, the safety and efficacy of which has not been fully evaluated by Regulatory Authorities, and which has not received marketing authorization in any country.
Call us or complete the form and our team will reach out soon to help determine your eligibility.
California: 619-489-5613
Michigan: 248-282-3640
